Wall Street analysts expect that BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will post $0.33 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Nine analysts have issued estimates for BioMarin Pharmaceutical’s earnings, with the lowest EPS estimate coming in at $0.23 and the highest estimate coming in at $0.45. BioMarin Pharmaceutical posted earnings of $0.14 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 135.7%. The firm is scheduled to report its next earnings results on Thursday, October 24th.
According to Zacks, analysts expect that BioMarin Pharmaceutical will report full-year earnings of $0.81 per share for the current financial year, with EPS estimates ranging from $0.59 to $0.90. For the next fiscal year, analysts forecast that the business will report earnings of $1.67 per share, with EPS estimates ranging from $0.97 to $2.54. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for BioMarin Pharmaceutical.
BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.16). BioMarin Pharmaceutical had a negative return on equity of 3.12% and a negative net margin of 7.19%. The firm had revenue of $388.00 million for the quarter, compared to analyst estimates of $415.03 million. During the same period in the previous year, the business posted ($0.09) EPS. BioMarin Pharmaceutical’s revenue for the quarter was up 4.0% compared to the same quarter last year.
Shares of NASDAQ:BMRN traded up $4.77 during trading on Tuesday, hitting $76.50. 1,825,500 shares of the stock were exchanged, compared to its average volume of 1,207,601. BioMarin Pharmaceutical has a 1-year low of $71.53 and a 1-year high of $106.74. The company has a market capitalization of $12.87 billion, a price-to-earnings ratio of -231.82 and a beta of 1.35. The company’s fifty day simple moving average is $80.43 and its 200-day simple moving average is $86.40. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.79 and a current ratio of 4.11.
In related news, Director V Bryan Lawlis sold 3,750 shares of the business’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $81.08, for a total value of $304,050.00. Following the sale, the director now owns 27,340 shares of the company’s stock, valued at approximately $2,216,727.20. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.90% of the stock is owned by insiders.
A number of institutional investors have recently bought and sold shares of BMRN. Rational Advisors LLC boosted its stake in BioMarin Pharmaceutical by 3,211.1% in the first quarter. Rational Advisors LLC now owns 298 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 289 shares in the last quarter. Doyle Wealth Management acquired a new position in BioMarin Pharmaceutical in the second quarter worth $26,000. Berman Capital Advisors LLC boosted its stake in BioMarin Pharmaceutical by 56.8% in the first quarter. Berman Capital Advisors LLC now owns 417 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 151 shares in the last quarter. Twin Tree Management LP acquired a new position in BioMarin Pharmaceutical in the first quarter worth $36,000. Finally, Trust Co. of Vermont acquired a new position in BioMarin Pharmaceutical in the first quarter worth $44,000. 96.86% of the stock is currently owned by institutional investors.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
See Also: What does a hold rating mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.